Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne) [7]

British Journal of Ophthalmology

Volumn 86, Issue 1, 2002, Pages 118-119

  Mandal, Nakul ^a   Chisholm, I H ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

AGE; BLINDNESS; CATARACT; CLINICAL FEATURE; GLAUCOMA; HUMAN; LETTER; LICENSING; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VISUAL AID;

AGED; COHORT STUDIES; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; PATIENT SELECTION; PHOTOSENSITIZING AGENTS; PORPHYRINS; PUVA THERAPY;

EID: 0036145176     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.86.1.118     Document Type: Letter

References (9)

1. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in AMD: One-year results of two randomised clinical trials-TAP Report 1
2. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in AMD: Two-year results of two randomised clinical trials-TAP Report 2
3. Use of eye care services among the 1991 Medicare population
4. Treatment of age-related macular degeneration
5. Laser treatment with verteporfin therapy and its potential impact on retinal practices
6. Age-related macular degeneration: New hope for a common problem comes from photodynamic therapy
7. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularisation in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes
8. Photodynamic therapy with verteporfin of the subfoveal choroidal neovascularisation in age-related macular degeneration: Study design and baseline characteristics in the VIP randomized clinical trials
9. Age-related macular degeneration best clinical practice guidelines